281 related articles for article (PubMed ID: 24603336)
21. p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.
Vaughan CA; Singh S; Windle B; Sankala HM; Graves PR; Andrew Yeudall W; Deb SP; Deb S
Arch Biochem Biophys; 2012 Feb; 518(1):79-88. PubMed ID: 22198284
[TBL] [Abstract][Full Text] [Related]
22. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
23. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
24. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
25. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells.
Yoshikawa K; Hamada J; Tada M; Kameyama T; Nakagawa K; Suzuki Y; Ikawa M; Hassan NM; Kitagawa Y; Moriuchi T
Biomed Res; 2010 Dec; 31(6):401-11. PubMed ID: 21187651
[TBL] [Abstract][Full Text] [Related]
26. Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.
Zhang P; Kitchen-Smith I; Xiong L; Stracquadanio G; Brown K; Richter PH; Wallace MD; Bond E; Sahgal N; Moore S; Nornes S; De Val S; Surakhy M; Sims D; Wang X; Bell DA; Zeron-Medina J; Jiang Y; Ryan AJ; Selfe JL; Shipley J; Kar S; Pharoah PD; Loveday C; Jansen R; Grochola LF; Palles C; Protheroe A; Millar V; Ebner DV; Pagadala M; Blagden SP; Maughan TS; Domingo E; Tomlinson I; Turnbull C; Carter H; Bond GL
Cancer Res; 2021 Apr; 81(7):1667-1680. PubMed ID: 33558336
[TBL] [Abstract][Full Text] [Related]
27. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
28. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
Dando I; Cordani M; Donadelli M
IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
[TBL] [Abstract][Full Text] [Related]
29. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
Kong LR; Ong RW; Tan TZ; Mohamed Salleh NAB; Thangavelu M; Chan JV; Koh LYJ; Periyasamy G; Lau JA; Le TBU; Wang L; Lee M; Kannan S; Verma CS; Lim CM; Chng WJ; Lane DP; Venkitaraman A; Hung HT; Cheok CF; Goh BC
Nat Commun; 2020 Apr; 11(1):2086. PubMed ID: 32350249
[TBL] [Abstract][Full Text] [Related]
30. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
[TBL] [Abstract][Full Text] [Related]
31. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
32. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
33. Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature.
Schaafsma E; Takacs EM; Kaur S; Cheng C; Kurokawa M
Sci Rep; 2022 Jan; 12(1):1317. PubMed ID: 35079034
[TBL] [Abstract][Full Text] [Related]
34. Systematic analysis of genotype-specific drug responses in cancer.
Kim N; He N; Kim C; Zhang F; Lu Y; Yu Q; Stemke-Hale K; Greshock J; Wooster R; Yoon S; Mills GB
Int J Cancer; 2012 Nov; 131(10):2456-64. PubMed ID: 22422301
[TBL] [Abstract][Full Text] [Related]
35. Do Mutations Turn p53 into an Oncogene?
Pitolli C; Wang Y; Mancini M; Shi Y; Melino G; Amelio I
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835684
[TBL] [Abstract][Full Text] [Related]
36. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
37. Gain of Function (GOF) Mutant p53 in Cancer-Current Therapeutic Approaches.
Roszkowska KA; Piecuch A; Sady M; Gajewski Z; Flis S
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362074
[TBL] [Abstract][Full Text] [Related]
38. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
[TBL] [Abstract][Full Text] [Related]
39. Towards the overcoming of anticancer drug resistance mediated by p53 mutations.
Cao X; Hou J; An Q; Assaraf YG; Wang X
Drug Resist Updat; 2020 Mar; 49():100671. PubMed ID: 31841768
[TBL] [Abstract][Full Text] [Related]
40. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database.
Li VD; Li KH; Li JT
J Cancer Res Clin Oncol; 2019 Mar; 145(3):625-636. PubMed ID: 30542790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]